Abionic SA Company Profile

09:53 EST 21st January 2020 | BioPortfolio

Abionic has developed and commercialized abioSCOPE, a rapid point of care diagnostic platform to improve medical diagnosis. This revolutionary nano-technology-based test system provides healthcare professionals with tools that help them to make a diagnosis from a single drop of patient’s blood. The first abioSCOPE applications are in allergy. Abionic already commercializes a test measuring total IgE and one used to detect the five main respiratory allergens.

News Articles [4 Associated News Articles listed on BioPortfolio]

Swiss biotech's sepsis assay can provide results in 5 minutes

Abionic, a Swiss diagnostics firm, has developed an assay that is capable of predicting within a 5-minute period which patien -More- 

Abionic Signs Agreement to Optimize Asthma Management in the U.S. through Innovative Rapid Point-of-Care Tests

In the U.S., 25 million people suffer from asthma, the majority of which have allergic asthma. Allergic asthma can be life threatening. This makes access to prompt, accurate diagnosis and appropri...

Abionic Integrates First Patients in US Clinical Trial for Sepsis Diagnosis Method

Abionic SA, Swiss Medtech firm based in Lausanne, is initiating a pivotal clinical trial in the US for an innovative point-of-care diagnostic method for sepsis to validate the results of a first tria...

Abionic: International Pivotal Study Successfully Demonstrates Diagnosis of Sepsis within 5 Minutes – 24 Hours Earlier Compared with Current Standard-of-Care

A breakthrough on sepsis diagnosis on today’s World Sepsis Day Every 3 seconds someone dies of sepsis globally. Sepsis is #1 killer at hospitals, it claims more lives than prostate cancer, breas...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Evaluation of Immunoassay Measurements of Pancreatic Stone Protein Performed on abioSCOPE® Device With the PSP Assay on ICU Patients at Risk of Sepsis as an Aid in Identifying Sepsis

This is a multicenter, prospective, biomarker-result-blinded observational study evaluating immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE devi...

Companies [2 Associated Companies listed on BioPortfolio]


Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abi...

Abionic SA

Abionic has developed and commercialized abioSCOPE, a rapid point of care diagnostic platform to improve medical diagnosis. This revolutionary nano-technology-based test system pr...

More Information about "Abionic SA" on BioPortfolio

We have published hundreds of Abionic SA news stories on BioPortfolio along with dozens of Abionic SA Clinical Trials and PubMed Articles about Abionic SA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Abionic SA Companies in our database. You can also find out about relevant Abionic SA Drugs and Medications on this site too.

Quick Search

Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Corporate Database Quicklinks

Searches Linking to this Company Record